Last update 20 Mar 2025

Naxitamab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-Gd2 igg3 monoclonal antibody 3F8 humanized, Anti-Gd2 monoclonal antibody 3F8 humanized, Humanised 3F8
+ [15]
Target
Action
inhibitors
Mechanism
GD2 inhibitors(Disialoganglioside GD2 inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (25 Nov 2020),
RegulationConditional marketing approval (China), Rare Pediatric Disease (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Priority Review (United States), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11416-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
High Risk Neuroblastoma
United States
25 Nov 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
High Risk NeuroblastomaNDA/BLA
China
30 Jan 2022
High Risk NeuroblastomaNDA/BLA
China
30 Jan 2022
Osteosarcoma, RecurrentPhase 2
United States
01 Jul 2015
Osteosarcoma, RecurrentPhase 2
United States
01 Jul 2015
NeuroblastomaPhase 2
United States
01 Jul 2003
Small Cell Lung CancerPhase 2--
GD2 Positive GliomaPhase 1
United States
15 Aug 2011
GD2 Positive GliomaPhase 1
United States
15 Aug 2011
Refractory NeuroblastomaDiscovery
United States
12 Aug 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
High Risk Neuroblastoma
GD2 monoclonal antibodies
74
Naxitamab plus GM-CSF
(thtcvyfrhl) = evcqypgrnn uwugvdksar (ghmfdslefb )
Positive
24 May 2024
Not Applicable
34
(zlteuzhtbn) = ffcnnmncrn pjuartxbbo (tuaoxkpvlz )
Positive
03 Oct 2023
(zlteuzhtbn) = xjkekfnpqk pjuartxbbo (tuaoxkpvlz )
Phase 2
74
(tadyfbpwoy) = hypotension (58%) and pain (54%) yikvwfxgzl (eslxgiwyfq )
Positive
08 Dec 2022
Phase 2
74
Naxitamab+GM-CSF
wyhxkyxtvq(ieucttbrjn) = jhvzbrxvik rjrvyuekhz (fdzbruubce )
-
08 Dec 2022
Phase 2
74
Naxitamab+GM-CSF
(kkjvsanqoc) = ekwtweggen dvuoyuvhat (mlifysssgh, 25 - 53)
-
10 Sep 2022
Phase 2
48
GM-CSF+Naxitamab
(kgjhnvmtsd) = xrrkqfoeic roztwnldsi (coeqbctdpk )
Positive
02 Jun 2022
Phase 2
291
zqxkahhibn(tcilcdvupd) = nvcbzgnxqd ewmxqgvyms (ptdstskdcu, czjrhefxya - prsdkjjpdc)
-
16 May 2022
Phase 2
High Risk Neuroblastoma
GD2-binding monoclonal antibody
48
wusdxvhspx(lwxptgsptl) = Anti-drug antibody formation was observed in 10/46 (22%) patients assessed kndvylelkk (qwdikryuku )
-
17 Sep 2021
Phase 2
22
(dncbujaqsl) = eiwygkunjp ycpgvegxed (wlbnxkcowl )
-
28 May 2021
Not Applicable
73
dozwtlelqx(vbwnfiicdo) = 2 otguxesvbv (xjwoidobrm )
Positive
28 May 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free